Breaking News Instant updates and real-time market news.

GILD

Gilead

$81.82

1.03 (1.27%)

, ABBV

AbbVie

$113.08

(0.00%)

09:44
02/15/18
02/15
09:44
02/15/18
09:44

Lawmakers to push for hep C drug patents being taken, Capitol Forum says

Representative Ro Khanna and 10 other Congress members plan to send a letter urging HHS Secretary Alex Azar to use his legal authority to take patents for hepatitis C virus drugs, according to The Capitol Forum, citing word from Khanna's office. Makers of hep C drugs include Gilead (GILD) and AbbVie (ABBV). Reference Link

GILD

Gilead

$81.82

1.03 (1.27%)

ABBV

AbbVie

$113.08

(0.00%)

  • 16

    Feb

  • 21

    Feb

  • 08

    Mar

GILD Gilead
$81.82

1.03 (1.27%)

01/31/18
JEFF
01/31/18
NO CHANGE
JEFF
Jefferies sees neutral impact on Biotech from State of the Union
Jefferies analyst Michael Yee sees a net neutral impact on Biotech stocks from President Trump's State of the Union speech last night. During the speech, Trump made comments about making lower drug prices a "priority" for the year, Yee tells investors in a research not titled "Drug Pricing Comments Not New or Surprising - But a Reminder of Rhetoric." The President, however, also commented on broader access to novel clinical trial drugs, Yee points out. After a "strong biotech rally" in January, the analyst assumes the sector, "at some point," will have some relative near-term pullback either on uncertainty about Trump commentary or some consolidation. Some of the analyst's Buy-rated names include AbbVie (ABBV), Amgen (AMGN), Eli Lilly (LLY) and Gilead Sciences (GILD).
02/07/18
SBSH
02/07/18
NO CHANGE
Target $105
SBSH
Buy
Gilead should be bought ahead of pipeline catalysts, says Citi
Citi analyst Robyn Karnauskas raised her price target for Gilead Sciences to $105 from $103 following last night's Q4 results. The analyst recommends buying the stock ahead of pipeline catalysts and keeps a Buy rating on the name. The base business seems to be stabilizing while gene therapy could be a potential growth area, Karnauskas tells investors in a post-earnings research note.
02/08/18
MSCO
02/08/18
NO CHANGE
MSCO
Equal Weight
Gilead Biktarvy approval, Glaxo patent suit not surprising, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison said investors expected Gilead (GILD) to receive FDA approval for its once-daily single tablet regimen to treat HIV-1 infection, now named Biktarvy, so he would expect limited impact on the stock from the news. He also said GlaxoSmithKline's (GSK) filing of patent infringement litigation alleging that Biktarvy infringes on ViiV's dolutegravir is not a surprise given prior comments by GSK and he would expect this to work through the courts. Harrison, who added that Biktarvy's clean label is a positive, keeps an Equal Weight rating on Gilead shares.
02/09/18
WELS
02/09/18
NO CHANGE
WELS
Outperform
Gilead should be bought on patent challenge weakness, says Wells Fargo
Wells Fargo analyst Jim Birchenough recommends buying Gilead Sciences on weakness following a patent infringement lawsuit against recently approved single tablet regimen Biktarvy for HIV. The analyst believes that Biktarvy patents will hold up to challenge and that the lawsuit will not impact launch or longer term value creation. He remains confident in Gilead's growth beyond "trough earnings" in 2018 and keeps an Outperform rating on the stock.
ABBV AbbVie
$113.08

(0.00%)

01/30/18
01/30/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AbbVie (ABBV) downgraded to Underperform from Market Perform by analyst Alex Arfaei, who said the risk/reward has "meaningfully changed" after the rise in the stock price, adding that the new focus on fundamentals beyond the benefits of tax reform suggests "significant price erosion in immunology driven by interchangeable biosimilar anti-TNFs, and lower effectiveness of the 'Rebate Trap' to block access to cheap biosimilars". 2. iRobot (IRBT) downgraded to Neutral from Buy at Sidoti by analyst Frank Camma, who cited valuation as shares approach his $98 price target. 3. Horizon Global (HZN) downgraded to Market Perform from Outperform at BMO Capital by analyst Gerrick Johnson, who said that while he still sees "strong demand in key end markets," operation execution, rising input costs, and high debt levels are concerning. The analyst added that the company may have "lost the faith of investors" after a 30% drop in the stock price following the guidance cut. 4. Yum! Brands (YUM) downgraded to Neutral from Buy at Nomura Instinet by analyst Mark Kalinowshi, who cited valuation and concerns a possible 2018 slowdown in U.S. same-store-sales. 5. Alaska Air (ALK) downgraded to Underweight from Neutral at JPMorgan by analyst Jamie Baker, who noted that the airline is the only name where he had to cut his 2019 estimates. He also believes the company "remains in the United crosshairs in San Francisco." The analyst also downgraded Southwest (LUV) to Neutral from Overweight, and said he believes better relative value exists elsewhere in the Airlines sector. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/02/18
ARGS
02/02/18
NO CHANGE
Target $145
ARGS
Buy
AbbVie price target raised to $145 from $120 at Argus
Argus analyst David Toung raised his price target on AbbVie to $145 and kept his Buy rating after a "solid" Q4 earnings report that also included a substantial boost from lower tax rates. Toung says AbbVie is likely to submit more applications for new products and expanded indications of existing drugs this year as it develops new growth drivers such as Imbruvica and Mavyret to complement the current large contribution from Humira.
02/05/18
JEFF
02/05/18
NO CHANGE
Target $25
JEFF
Hold
Acorda remains takeover candidate after competitor data, says Jefferies
Jefferies analyst Michael Yee believes the positive Phase III topline results from Acorda Therapeutics (ACOR) competitor Sunovion for APL-130277 in Parkinson's patients came in as expected. While APL-130277 data compares favorably over Inbrija's 3.92 point difference at week 12, Yee cautions to compare directly head-to-head since patient baseline characteristics could be different. Acorda remains a "reasonably likely" acquisition candidate in 2018 given its $300M-$500M-plus Parkinson's asset Inbrija, Yee tells investors in a research note. The analyst does not think Biogen (BIIB) should buy the company, but sees other potential suitors in AbbVie (ABBV), Allergan (AGN), Mitsubishi, Roche (RHHBY) and Shire (SHPG). He believes a takeover price could be north of $2B. Yee keeps a Hold rating on Acorda with a $25 price target.

TODAY'S FREE FLY STORIES

BRN

Barnwell Industries

$1.30

(0.00%)

06:10
03/22/19
03/22
06:10
03/22/19
06:10
Hot Stocks
Barnwell Industries announces real estate transaction through KD »

Barnwell Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STX

Seagate

$48.95

2.73 (5.91%)

, HPE

HP Enterprise

$16.03

0.15 (0.94%)

06:09
03/22/19
03/22
06:09
03/22/19
06:09
Periodicals
Seagate teams up with HPE, Nvidia for Project Athena, DigiTimes reports »

Seagate (STX) has…

STX

Seagate

$48.95

2.73 (5.91%)

HPE

HP Enterprise

$16.03

0.15 (0.94%)

NVDA

Nvidia

$183.92

9.54 (5.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 03

    Apr

ESALY

Eisai

$0.00

(0.00%)

06:06
03/22/19
03/22
06:06
03/22/19
06:06
Downgrade
Eisai rating change  »

Eisai downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVA

Covanta

$17.04

0.27 (1.61%)

06:05
03/22/19
03/22
06:05
03/22/19
06:05
Hot Stocks
Covanta, Green Investment Group reach financial close on Rookery project »

Covanta and Green…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

GBX

Greenbrier

$37.33

0.45 (1.22%)

06:05
03/22/19
03/22
06:05
03/22/19
06:05
Earnings
Greenbrier reports preliminary Q2 EPS 7c-9c, consensus 42c »

Reports preliminary Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$166.08

0.61 (0.37%)

06:05
03/22/19
03/22
06:05
03/22/19
06:05
Periodicals
Facebook knew about data misuse earlier than reported, Guardian says »

Facebook knew about…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 03

    Apr

  • 04

    Apr

NKE

Nike

$88.05

1.3597 (1.57%)

06:04
03/22/19
03/22
06:04
03/22/19
06:04
Recommendations
Nike analyst commentary  »

Nike price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Apr

  • 04

    Apr

GTLS

Chart Industries

$94.49

2.06 (2.23%)

, BHGE

Baker Hughes

$28.50

0.24 (0.85%)

06:03
03/22/19
03/22
06:03
03/22/19
06:03
Hot Stocks
Chart Industries books $135M order »

Chart Industries (GTLS)…

GTLS

Chart Industries

$94.49

2.06 (2.23%)

BHGE

Baker Hughes

$28.50

0.24 (0.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 22

    May

  • 28

    May

  • 28

    May

AAPL

Apple

$195.07

6.93 (3.68%)

06:01
03/22/19
03/22
06:01
03/22/19
06:01
Periodicals
Apple signs Vox to be part of news subscription service, Bloomberg reports »

Apple has signed Vox to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

LIND

Lindblad Expeditions

$15.18

-0.12 (-0.78%)

05:55
03/22/19
03/22
05:55
03/22/19
05:55
Conference/Events
Lindblad Expeditions management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

DRI

Darden

$116.11

7.485 (6.89%)

05:53
03/22/19
03/22
05:53
03/22/19
05:53
Recommendations
Darden analyst commentary  »

Darden price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMC

Commercial Metals

$17.35

1.29 (8.03%)

05:43
03/22/19
03/22
05:43
03/22/19
05:43
Upgrade
Commercial Metals rating change  »

Commercial Metals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWK

Stanley Black & Decker

$134.59

2.69 (2.04%)

05:42
03/22/19
03/22
05:42
03/22/19
05:42
Upgrade
Stanley Black & Decker rating change  »

Stanley Black &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Apr

  • 24

    Apr

BIIB

Biogen

$226.71

-93.76 (-29.26%)

05:42
03/22/19
03/22
05:42
03/22/19
05:42
Downgrade
Biogen rating change  »

Biogen downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 24

    Apr

  • 30

    Apr

  • 01

    May

  • 28

    May

BBY

Best Buy

$70.56

1.44 (2.08%)

05:41
03/22/19
03/22
05:41
03/22/19
05:41
Upgrade
Best Buy rating change  »

Best Buy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VAR

Varian Medical

$137.77

1.97 (1.45%)

05:41
03/22/19
03/22
05:41
03/22/19
05:41
Upgrade
Varian Medical rating change  »

Varian Medical upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

BIIB

Biogen

$226.71

-93.76 (-29.26%)

05:41
03/22/19
03/22
05:41
03/22/19
05:41
Downgrade
Biogen rating change at Citi »

Citi downgrades Biogen to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 24

    Apr

  • 30

    Apr

  • 01

    May

  • 28

    May

FTI

TechnipFMC

$23.83

0.09 (0.38%)

05:40
03/22/19
03/22
05:40
03/22/19
05:40
Upgrade
TechnipFMC rating change  »

TechnipFMC upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

RYB

RYB Education

$8.01

0.09 (1.14%)

05:40
03/22/19
03/22
05:40
03/22/19
05:40
Downgrade
RYB Education rating change  »

RYB Education downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOV

Spark Networks

$11.29

(0.00%)

05:26
03/22/19
03/22
05:26
03/22/19
05:26
Conference/Events
Spark Networks to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

ESALY

Eisai

$0.00

(0.00%)

05:25
03/22/19
03/22
05:25
03/22/19
05:25
Downgrade
Eisai rating change  »

Eisai downgraded to Sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESALY

Eisai

$0.00

(0.00%)

, BIIB

Biogen

$226.71

-93.76 (-29.26%)

05:24
03/22/19
03/22
05:24
03/22/19
05:24
Hot Stocks
Eisai announces initiation of Phase III BAN2401 study in Alzheimer's disease »

Eisai (ESALY) announced…

ESALY

Eisai

$0.00

(0.00%)

BIIB

Biogen

$226.71

-93.76 (-29.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 24

    Apr

  • 30

    Apr

  • 01

    May

  • 28

    May

ZUO

Zuora

$24.34

0.62 (2.61%)

05:18
03/22/19
03/22
05:18
03/22/19
05:18
Recommendations
Zuora analyst commentary at Jefferies »

Zuora business metrics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

OPHRY

Ophir Energy

$0.00

(0.00%)

05:15
03/22/19
03/22
05:15
03/22/19
05:15
Downgrade
Ophir Energy rating change  »

Ophir Energy downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TELNY

Telenor

$0.00

(0.00%)

05:13
03/22/19
03/22
05:13
03/22/19
05:13
Downgrade
Telenor rating change  »

Telenor downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.